Dendrimers for enhanced drug solubilization.

Approximately 40% of newly developed drugs are rejected by the pharmaceutical industry and will never benefit a patient because of low water solubility. Another 17% of launched drugs exhibit suboptimal performance for the same reason. Given the growing impact and need for drug delivery, a thorough understanding of delivery technologies that enhance the bioavailability of drugs is important. The high level of control over the dendritic architecture (size, branching density, surface functionality) makes dendrimers ideal excipients for enhanced solubility of poorly water-soluble drugs. Many commercial small-molecule drugs with anticancer, anti-inflammatory and antimicrobial activity have been formulated successfully with dendrimers, such as poly(amidoamine) (PAMAM), poly(propylene imine) (PPI or DAB) and poly(etherhydroxylamine) (PEHAM). Some dendrimers themselves show pharmaceutical activity in these three areas, providing the opportunity for combination therapy in which the dendrimers serve as the drug carrier and simultaneously as an active part of the therapy.